Table of Contents:

1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.1.1 Drivers
4.1.1.1 Increasing occurrences of chronic diseases
4.1.1.2 Growth in Abbreviated New Drug Applications (ANDA)
4.1.1.3 Rising acceptance and uptake of biopharmaceuticals
4.1.1.4 Growing importance of generics
4.1.2 Restraints
4.1.2.1 Stringent regulatory policies
4.1.2.2 Adverse drug price control policies across numerous countries
4.1.3 Opportunities
4.1.3.1 Emerging biosimilar market
4.2 Increasing scope for high-potency active pharmaceutical ingredients
4.3 Macroeconomic indicators
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 Research &Development
5.2.2 Manufacturing
5.2.3 Distribution
5.2.4 Marketing & Sales
5.2.5 Post-Sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
6 Global Active Pharmaceutical Ingredients Market, by Manufacturing Process
6.1 Introduction
6.1.1 Captive Manufacturing
6.1.2 Contract Manufacturing
7 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis
7.1 Introduction
7.2 Synthetic
7.3 Biotech
7.3.1 Monoclonal Antibodies
7.3.2 Recombinant proteins
7.3.3 Vaccines
7.3.4 Others
8 Global Active Pharmaceutical Ingredients Market, by API Formulation
8.1 Introduction
8.2 Generic API
8.3 Branded/ Innovative API
9 Global Active Pharmaceutical Ingredients Market, by Application
9.1 Introduction
9.2 Cardiovascular Disease
9.3 Oncology
9.4 Neurological Disorders
9.5 Orthopedic Disorders
9.6 Respiratory
9.7 Gastrointestinal Disorders
9.8 Urology
9.9 Others
10 Global Active Pharmaceutical Ingredients Market, by Molecule
10.1 Introduction
10.2 Molecule
10.3 Large Molecule
10.4 Small Molecule
11 Global Active Pharmaceutical Ingredients Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 UK
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Asia Pacific
11.4.2 Japan
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Republic of Korea
11.4.7 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 Middle East and Africa
11.5.2 Middle East
11.5.2.1 Saudi Arabia
?
11.5.3 Africa
11.5.3.1 North Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
12.2 Merger and Acquisition
12.3 Major Strategies adopted by market players
12.4 Competitive Landscape
12.4.1 Introduction
12.4.2 Strategic Partnership
12.5 Key Developments
12.6 Potential Molecules
13 Company Profiles
13.1 Sanofi
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Bayer AG
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Pfizer Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
?
13.4 F. Hoffmann-La Roche AG
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Abbott Laboratories
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Merck & Co., Inc.
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Boehringer Ingelheim GmbH
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Glaxosmithkline Plc (GSK)
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 Novartis AG
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 Eli Lilly and Company
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Teva Pharmaceutical Industries Ltd
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO's Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
15.1.1 References
1 Report Prologue
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.1.1 Drivers
4.1.1.1 Increasing occurrences of chronic diseases
4.1.1.2 Growth in Abbreviated New Drug Applications (ANDA)
4.1.1.3 Rising acceptance and uptake of biopharmaceuticals
4.1.1.4 Growing importance of generics
4.1.2 Restraints
4.1.2.1 Stringent regulatory policies
4.1.2.2 Adverse drug price control policies across numerous countries
4.1.3 Opportunities
4.1.3.1 Emerging biosimilar market
4.2 Increasing scope for high-potency active pharmaceutical ingredients
4.3 Macroeconomic indicators
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.2.1 Research &Development
5.2.2 Manufacturing
5.2.3 Distribution
5.2.4 Marketing & Sales
5.2.5 Post-Sales Monitoring
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
6 Global Active Pharmaceutical Ingredients Market, by Manufacturing Process
6.1 Introduction
6.1.1 Captive Manufacturing
6.1.2 Contract Manufacturing
7 Global Active Pharmaceutical Ingredients Market, by Type of Synthesis
7.1 Introduction
7.2 Synthetic
7.3 Biotech
7.3.1 Monoclonal Antibodies
7.3.2 Recombinant proteins
7.3.3 Vaccines
7.3.4 Others
8 Global Active Pharmaceutical Ingredients Market, by API Formulation
8.1 Introduction
8.2 Generic API
8.3 Branded/ Innovative API
9 Global Active Pharmaceutical Ingredients Market, by Application
9.1 Introduction
9.2 Cardiovascular Disease
9.3 Oncology
9.4 Neurological Disorders
9.5 Orthopedic Disorders
9.6 Respiratory
9.7 Gastrointestinal Disorders
9.8 Urology
9.9 Others
10 Global Active Pharmaceutical Ingredients Market, by Molecule
10.1 Introduction
10.2 Molecule
10.3 Large Molecule
10.4 Small Molecule
11 Global Active Pharmaceutical Ingredients Market, by Region
11.1 Introduction
11.2 Americas
11.2.1 North America
11.2.1.1 U.S.
11.2.1.2 Canada
11.2.2 South America
11.3 Europe
11.3.1 Western Europe
11.3.1.1 Germany
11.3.1.2 France
11.3.1.3 UK
11.3.1.4 Italy
11.3.1.5 Spain
11.3.1.6 Rest of Western Europe
11.3.2 Eastern Europe
11.4 Asia Pacific
11.4.1 Asia Pacific
11.4.2 Japan
11.4.3 China
11.4.4 India
11.4.5 Australia
11.4.6 Republic of Korea
11.4.7 Rest of Asia Pacific
11.5 The Middle East & Africa
11.5.1 Middle East and Africa
11.5.2 Middle East
11.5.2.1 Saudi Arabia
?
11.5.3 Africa
11.5.3.1 North Africa
12 Competitive Landscape
12.1 Company Market Share Analysis
12.1.1 Introduction
12.2 Merger and Acquisition
12.3 Major Strategies adopted by market players
12.4 Competitive Landscape
12.4.1 Introduction
12.4.2 Strategic Partnership
12.5 Key Developments
12.6 Potential Molecules
13 Company Profiles
13.1 Sanofi
13.1.1 Company Overview
13.1.2 Financial Overview
13.1.3 Products Offering
13.1.4 Key Developments
13.1.5 SWOT Analysis
13.1.6 Key Strategy
13.2 Bayer AG
13.2.1 Company Overview
13.2.2 Financial Overview
13.2.3 Products Offering
13.2.4 Key Developments
13.2.5 SWOT Analysis
13.2.6 Key Strategy
13.3 Pfizer Inc.
13.3.1 Company Overview
13.3.2 Financial Overview
13.3.3 Products Offering
13.3.4 Key Developments
13.3.5 SWOT Analysis
13.3.6 Key Strategy
?
13.4 F. Hoffmann-La Roche AG
13.4.1 Company Overview
13.4.2 Financial Overview
13.4.3 Products Offering
13.4.4 Key Developments
13.4.5 SWOT Analysis
13.4.6 Key Strategy
13.5 Abbott Laboratories
13.5.1 Company Overview
13.5.2 Financial Overview
13.5.3 Products Offering
13.5.4 Key Developments
13.5.5 SWOT Analysis
13.5.6 Key Strategy
13.6 Merck & Co., Inc.
13.6.1 Company Overview
13.6.2 Financial Overview
13.6.3 Products Offering
13.6.4 Key Developments
13.6.5 SWOT Analysis
13.6.6 Key Strategy
13.7 Boehringer Ingelheim GmbH
13.7.1 Company Overview
13.7.2 Financial Overview
13.7.3 Products Offering
13.7.4 Key Developments
13.7.5 SWOT Analysis
13.7.6 Key Strategy
13.8 Glaxosmithkline Plc (GSK)
13.8.1 Company Overview
13.8.2 Financial Overview
13.8.3 Products Offering
13.8.4 Key Developments
13.8.5 SWOT Analysis
13.8.6 Key Strategy
13.9 Novartis AG
13.9.1 Company Overview
13.9.2 Financial Overview
13.9.3 Products Offering
13.9.4 Key Developments
13.9.5 SWOT Analysis
13.9.6 Key Strategy
13.1 Eli Lilly and Company
13.10.1 Company Overview
13.10.2 Financial Overview
13.10.3 Products Offering
13.10.4 Key Developments
13.10.5 SWOT Analysis
13.10.6 Key Strategy
13.11 Teva Pharmaceutical Industries Ltd
13.11.1 Company Overview
13.11.2 Financial Overview
13.11.3 Products Offering
13.11.4 Key Developments
13.11.5 SWOT Analysis
13.11.6 Key Strategy
14 Conclusion
14.1 Key Findings
14.1.1 CEO's Viewpoint
14.1.2 Unmet Needs
14.1.3 Key Companies to Watch
14.1.4 Prediction
15 Appendix
15.1 Discussion Blue Print
15.1.1 References